Class information for:
Level 1: GEFITINIB//ERLOTINIB//EGFR MUTATION

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
362 3515 40.9 88%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
823 11253 NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 GEFITINIB Author keyword 331 42% 17% 602
2 ERLOTINIB Author keyword 214 36% 14% 476
3 EGFR MUTATION Author keyword 172 54% 6% 223
4 AFATINIB Author keyword 78 59% 3% 88
5 EGFR MUTATIONS Author keyword 75 58% 3% 88
6 EGFR Author keyword 74 12% 17% 586
7 EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION Author keyword 59 69% 1% 50
8 EPIDERMAL GROWTH FACTOR RECEPTOR Author keyword 54 12% 12% 416
9 EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR Author keyword 49 66% 1% 45
10 T790M Author keyword 44 66% 1% 41

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 GEFITINIB 331 42% 17% 602 Search GEFITINIB Search GEFITINIB
2 ERLOTINIB 214 36% 14% 476 Search ERLOTINIB Search ERLOTINIB
3 EGFR MUTATION 172 54% 6% 223 Search EGFR+MUTATION Search EGFR+MUTATION
4 AFATINIB 78 59% 3% 88 Search AFATINIB Search AFATINIB
5 EGFR MUTATIONS 75 58% 3% 88 Search EGFR+MUTATIONS Search EGFR+MUTATIONS
6 EGFR 74 12% 17% 586 Search EGFR Search EGFR
7 EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION 59 69% 1% 50 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+MUTATION Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+MUTATION
8 EPIDERMAL GROWTH FACTOR RECEPTOR 54 12% 12% 416 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR
9 EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 49 66% 1% 45 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+TYROSINE+KINASE+INHIBITOR Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+TYROSINE+KINASE+INHIBITOR
10 T790M 44 66% 1% 41 Search T790M Search T790M

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 GEFITINIB 615 36% 40% 1397
2 ERLOTINIB 523 45% 25% 882
3 EGFR MUTATIONS 418 55% 15% 517
4 GEFITINIB SENSITIVITY 187 73% 4% 141
5 PREVIOUSLY TREATED PATIENTS 180 41% 10% 340
6 FACTOR RECEPTOR MUTATIONS 171 60% 5% 188
7 T790M MUTATION 151 88% 2% 72
8 GEFITINIB THERAPY 125 73% 3% 95
9 ACQUIRED RESISTANCE 124 19% 17% 605
10 EGFR MUTATION 107 57% 4% 127

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 JOURNAL OF THORACIC ONCOLOGY 34 12% 8% 274
2 CLINICAL LUNG CANCER 15 15% 3% 95

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer 2015 6 45 93%
Acquired resistance to TKIs in solid tumours: learning from lung cancer 2014 36 68 65%
Epidermal growth factor receptor mutations in lung cancer 2007 958 165 51%
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis 2013 83 44 75%
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease 2013 87 94 71%
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer 2010 299 158 67%
The quest to overcome resistance to EGFR-targeted therapies in cancer 2013 107 170 54%
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors 2015 2 55 93%
Drug therapy: EGFR antagonists in cancer treatment 2008 761 94 46%
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples 2013 51 86 85%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 THORAC ONCOL SERV 30 37% 1.8% 64
2 GUANGDONG LUNG CANC 27 42% 1.4% 49
3 LOWE THORAC ONCOL 21 34% 1.5% 51
4 HEMATOL ONCOL P MED 9 23% 1.0% 35
5 THORAC ONCOL SERV SOLID TUMOR ONCOL 9 83% 0.1% 5
6 USP DEXEUS UNIV 6 100% 0.1% 4
7 GUANGZHOU TECHNOL INNOVAT BASE 5 60% 0.2% 6
8 MED MED ONCOL PATHOL 5 60% 0.2% 6
9 SIR YK PAU CANC 5 60% 0.2% 6
10 STATE SOUTH CHINA 5 54% 0.2% 7

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000221509 CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK
2 0.0000207376 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
3 0.0000201838 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
4 0.0000135079 NIMOTUZUMAB//H R3//CETUXIMAB
5 0.0000118127 EGF POLYMORPHISM//GEFITINIB THERAPY//INTRON 1 POLYMORPHISM
6 0.0000096755 BRONCHIOLOALVEOLAR CARCINOMA//BRONCHORRHEA//ATYPICAL ADENOMATOUS HYPERPLASIA
7 0.0000087310 ANILINOQUINAZOLINE//COMBI MOLECULE//CANC DRUG
8 0.0000085385 ERCC1//RRM1//MED OVARIAN CANC SECT
9 0.0000064767 SW MED SIMMONS CANC//COPY NUMBER LOSS//K RAS GENOTYPES
10 0.0000064073 PANITUMUMAB//CETUXIMAB//METASTATIC COLORECTAL CANCER